[HTML][HTML] Neoadjuvant treatments for triple-negative breast cancer (TNBC)
G Von Minckwitz, M Martin - Annals of oncology, 2012 - Elsevier
Neoadjuvant chemotherapy provides a means both of improving subsequent surgical
intervention and of testing novel therapies or combinations. Historically, triple-negative …
intervention and of testing novel therapies or combinations. Historically, triple-negative …
Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
H Yamauchi, M Toi, S Takayama, S Nakamura… - Breast Cancer, 2023 - Springer
Background The efficacy and safety of olaparib compared with placebo in the subset of
patients from Japan in the phase 3 OlympiA trial (NCT02032823) are reported here and …
patients from Japan in the phase 3 OlympiA trial (NCT02032823) are reported here and …
Combination of olaparib with radiotherapy for triple‐negative breast cancers: one‐year toxicity report of the RADIOPARP phase I trial
P Loap, D Loirat, F Berger, K Cao… - … journal of cancer, 2021 - Wiley Online Library
Triple‐negative breast cancer (TNBC) cells are sensitive to PARP1 inhibitors in vitro. The
combination of Olaparib and radiotherapy for TNBC is currently evaluated in the Phase I …
combination of Olaparib and radiotherapy for TNBC is currently evaluated in the Phase I …
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
JK Litton, JT Beck, JM Jones, J Andersen… - The …, 2023 - academic.oup.com
Background The undetermined efficacy of the current standard-of-care neoadjuvant
treatment, anthracycline/platinum-based chemotherapy, in patients with early-stage triple …
treatment, anthracycline/platinum-based chemotherapy, in patients with early-stage triple …
[HTML][HTML] Translating the role of PARP inhibitors in triple-negative breast cancer
M Beniey, T Haque, S Hassan - Oncoscience, 2019 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive subtype of breast
cancer that lacks expression of estrogen receptor (ER), progesterone receptor (PR), and …
cancer that lacks expression of estrogen receptor (ER), progesterone receptor (PR), and …
Combination of olaparib and radiation therapy for triple negative breast cancer: preliminary results of the RADIOPARP phase 1 trial
P Loap, D Loirat, F Berger, F Ricci… - International Journal of …, 2021 - Elsevier
Purpose Preclinical studies have evidenced that triple-negative breast cancer (TNBC) cell
lines are more sensitive to poly (ADP-ribose) polymerase inhibitors. This provides a strong …
lines are more sensitive to poly (ADP-ribose) polymerase inhibitors. This provides a strong …
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Background The randomized, double-blind OlympiA trial compared 1 year of the oral poly
(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as …
(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as …
Which patients do we need to test for BRCA1/2 mutation? Feasibility of adjuvant olaparib treatment in early breast cancer–real-world data from two large German …
Simple Summary Targeted therapies are increasingly used in patients with early breast
cancer and a high clinical risk of relapse. Patients with clinical high-risk HER2-negative …
cancer and a high clinical risk of relapse. Patients with clinical high-risk HER2-negative …
[HTML][HTML] Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination …
PA Fasching, T Link, J Hauke, F Seither, C Jackisch… - Annals of …, 2021 - Elsevier
Background The efficacy and toxicity of olaparib as combination therapy in early breast
cancer (BC) patients with homologous recombinant deficiency (HRD)[score high and/or …
cancer (BC) patients with homologous recombinant deficiency (HRD)[score high and/or …
CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT)+/-carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast …
WM Sikov, MY Polley, E Twohy, CM Perou, B Singh… - 2019 - ascopubs.org
591 Background: Both Cb and Bev demonstrate activity when combined with standard
chemotherapy in TNBC. CALGB 40603 is a 2x2 randomized trial that previously …
chemotherapy in TNBC. CALGB 40603 is a 2x2 randomized trial that previously …